When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Authors:
- 15 February 2018
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 34 (4) , e2981
Abstract
Summary: The newer oral therapies for type 2 diabetes mellitus, dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors, have advantages over older agents. Dipeptidyl peptidase‐4 inhibitors are weight neutral and have few adverse effects. Sodium glucose cotransporter 2 inhibitors have additional benefits: weight loss, blood pressure reduction, cardiovascular risk reduction, and renoprotective effects. Sodium glucose cotransporter 2 inhibitors have increased risk of urogenital infections and possible risk of “euglycaemic” diabetic ketoacidosis. It is important to balance the benefits over the older‐oral therapies as these agents are more expensive; yet some analyses suggest that they are within the limits of what is considered cost‐effective in health care. We discuss the relative merits and drawbacks of these 2 classes and consider their roles in the treatment of type 2 diabetes mellitus. We suggest a number of patient profiles where early use of these agents could be used. We favour the use of SGLT2 inhibitors over DPP‐4 inhibitors as add on therapy to metformin when glycaemic targets have not been achieved given their similar glycaemic efficacy and the additional benefits of SGLT2 inhibitors. We particularly favour SGLT2 inhibitors in those where additional weight loss and blood pressure reductions are desired, and in patients with heart failure or cardiovascular disease. Care should be taken to warn patients about genital fungal infections and to avoid use in people with risk factors for SGLT2 associated ketoacidosis. We favour DPP‐4 inhibitors in those where side effects of other agents are of concern, the frail elderly population, and those with renal disease precluding SGTL2 inhibitor use.Keywords
Funding Information
- AstraZeneca
This publication has 119 references indexed in Scilit:
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- One‐Year Changes in Symptoms of Depression and Weight in Overweight/Obese Individuals With Type 2 Diabetes in the Look AHEAD StudyObesity, 2012
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific DeathNew England Journal of Medicine, 2011
- Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes MellitusArchives of internal medicine (1960), 2010
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 DiabetesThe Sleep AHEAD StudyEffect of Weight Loss on Obstructive Sleep ApneaArchives of internal medicine (1960), 2009
- Impact of a Weight Management Program on Health-Related Quality of Life in Overweight Adults With Type 2 DiabetesArchives of internal medicine (1960), 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factorsPostgraduate Medical Journal, 2006